← FDA DRUG APPROVALS

FDA ANDA · ANDA065022

BACITRACIN ZINC AND POLYMYXIN B SULFATE

Sponsor: PADAGIS US

APPLICATION
ANDA065022
TYPE
ANDA
ORIGINAL APPROVAL
2002-02-27
LATEST ACTION
2014-08-15
ROUTE
OPHTHALMIC
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued

Products

BACITRACIN ZINC AND POLYMYXIN B SULFATEDiscontinued
BACITRACIN ZINC 500 UNITS/GM, POLYMYXIN B SULFATE 10,000 UNITS/GM · OINTMENT · OPHTHALMIC

Approval history

2014-08-15Manufacturing (CMC) · Supplement 4AP
2002-02-27OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →